Treatment With VYXEOS

Learn how you or your loved one will receive treatment with VYXEOS. Use the links below to explore this page.

On this page:

VYXEOS is administered as an intravenous (IV) infusion using a central IV line or peripherally inserted central catheter. It will be given in cycles, and your doctor will determine how many cycles of therapy you will receive for your AML.

IV bag icon

When you receive your infusion, you may notice that the VYXEOS solution is purple.

Induction with VYXEOS for AML

Initial cycle(s), called induction, is intended to control the disease and reduce the number of leukemia cells. Most patients will require several weeks of hospital stay to monitor blood counts and manage potential complications.

Some patients may receive a second cycle of induction treatment. Your healthcare team will help determine what is best for you.

Induction dosing schedule

Consolidation with VYXEOS for AML

Subsequent cycle(s), called consolidation, may be given to ensure the disease is being controlled and the number of leukemia cells continues to be reduced.

Not all patients receive consolidation treatment, but those who do may receive up to 2 cycles. Your healthcare team will help determine what is best for you.

Consolidation dosing schedule

How do I know if VYXEOS is working?

A bone marrow exam can be done 2 to 3 weeks after treatment to look for the presence of leukemia cells to see if VYXEOS is working.

What to tell your healthcare team before treatment with VYXEOS

Known or suspected pregnancy. VYXEOS can harm your unborn baby and should not be received during pregnancy. Females and males of reproductive age should use effective contraception during treatment and for 6 months following the last dose of VYXEOS. Additionally, you should not breastfeed during treatment with VYXEOS and for at least 2 weeks after the last dose.

History of heart disease. VYXEOS can cause heart-related side effects. Tell your healthcare team about any history of heart disease, radiation to the chest, or previous chemotherapy.

History of copper-processing disorder. VYXEOS contains copper and may cause copper overload in patients with Wilson’s disease or other copper-processing disorders.

Additional medications you may be taking. It is important to tell your healthcare team about all medications you may be taking, including any vitamins or supplements, to determine what you may need to discontinue during treatment. Some medications may affect treatment with VYXEOS.

What to tell your healthcare team during treatment with VYXEOS

You should immediately contact a member of your healthcare team if you experience any of the following:

Fever, signs of infection, or bruising or bleeding. VYXEOS can cause a severe decrease in blood cells (white and red blood cells and cells that prevent bleeding, called platelets), which can result in serious infection and/or bleeding and possibly lead to death. Your doctor will monitor your blood counts during treatment with VYXEOS. You should tell your doctor about new onset fever or symptoms of infection or if you notice signs of bruising or bleeding.

Signs of heart failure. VYXEOS can cause heart-related side effects such as shortness of breath or trouble breathing; swelling or fluid retention, especially in the feet, ankles, or legs; or unusual tiredness.

Skin damage. VYXEOS can damage the skin if it leaks out of the vein. Tell your doctor right away if you experience symptoms of burning, stinging, or blisters and skin sores at the injection site.

Signs of hypersensitivity reactions, including anaphylaxis. VYXEOS may cause allergic reactions, including anaphylaxis. Seek immediate medical attention if you develop signs and symptoms of anaphylaxis, such as difficulty breathing, severe itching, skin rash or hives, or swelling of the face, lips, mouth, or tongue.

These are not all of the possible side effects of VYXEOS. Be sure to speak to your healthcare team about any side effects you have. You will also have blood tests done to check for side effects during treatment with VYXEOS.

What is VYXEOS?

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is an intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia (AML). These types include patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).

Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.

Important Safety Information